Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Biohaven Pharmaceutical Jumped 20% Today

By Brian Orelli, PhD – Apr 12, 2019 at 6:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Rumor has it that the drugmaker is up for sale.

What happened

Shares of Biohaven Pharmaceutical (BHVN -9.65%) closed up 20% on Friday after Bloomberg reported that the drugmaker is exploring options, including the potential sale of the company. Unnamed sources claim that Biohaven has attracted interest from potential bidders.

So what

Biohaven is developing drugs for migraines, an indication that requires a large sales force to have an effective launch, so it's not hard to see how the company could be more valuable to a large pharma than the valuation that investors are willing to ascribe to the company.

It remains to be seen whether a large drugmaker would be willing to buy Biohaven, and at what price. Even before today's jump, shares had doubled over the last year or so.

Investors sent Biohaven's shares down in March of 2018 following fairly lackluster data for its lead drug candidate, rimegepant. While the data showed the drug was better than placebo in helping patients with acute migraine, it didn't appear as good as Eli Lilly's (LLY 0.33%) lasmiditan.

But investors have warmed to the drug after additional phase 3 studies confirmed it was working, and it certainly appears approvable. The company plans to submit rimegepant to the Food and Drug Administration this quarter, setting up a potential approval late this year.

Biohaven also has BHV-3500, another migraine drug, which is delivered through the nose. The drug recently entered phase 2/3 testing, with data expected in the fourth quarter of this year.

For Sale sign

Image source: Getty Images.

Now what

At this point, investors need to make sure they're buying for the right reason. Chasing a potential acquisition can result in disaster if the sale doesn't come to fruition. Putting out a "for sale" sign isn't a guarantee that a company will be able to get an offer at an acceptable price.

Of course, if you think Biohaven is still undervalued while remaining independent, it's reasonable to buy at these inflated prices. Just realize that at a market cap of $2.5 billion, quite a lot of sales are already priced into the drugmaker's valuation.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biohaven Pharmaceutical Holding Company Ltd. Stock Quote
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$14.32 (-9.65%) $-1.53
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$366.46 (0.33%) $1.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.